Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1C | P00326 | 2/20 | 0.42 |
| ▸ | ADH1A | P07327 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21183554 | 0.80 | RAB9A (0.52) | SMN1; SMN2RAB9A | |
| SCHEMBL19974902 | 0.80 | ADH1C (0.41) | ADH1CADH1AADH1BEPHX1 | |
| SCHEMBL21183526 | 0.80 | ADH1A (0.49) | ADH1CADH1AADH1BSMN1; SMN2GAA | |
| SCHEMBL21183524 | 0.79 | ADH1A (0.47) | ADH1CADH1AADH1BSMN1; SMN2GAA | |
| SCHEMBL19974720 | 0.79 | ADH1C (0.47) | ADH1CADH1AADH1BSMN1; SMN2GAA | |
| SCHEMBL21183539 | 0.78 | ADH1A (0.46) | ADH1CADH1AADH1BEPHX1 | |
| SCHEMBL21183568 | 0.77 | PARP10 (0.43) | SMN1; SMN2RAB9A | |
| SCHEMBL21176367 | 0.77 | ADH1B (0.40) | ADH1CADH1AADH1BSMN1; SMN2GAA | |
| SCHEMBL19975272 | 0.77 | ADH1A (0.45) | ADH1CADH1AADH1B | |
| SCHEMBL19982895 | 0.77 | ADH1B (0.38) | ADH1CADH1AADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| CN-110062753-A | Antiviral compounds | 哈普洛根有限责任公司 | 2019-07-26 | — | — | CN | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | ADH1C 3925/4885ADH1A 3054/4885ADH1B 1889/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | ADH1C 3739/4885ADH1A 2909/4885ADH1B 2084/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | ADH1C 3925/4885ADH1A 3054/4885ADH1B 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.